Eczema Drug-Free Remission Data Headlines SID 2026

The Society for Investigative Dermatology Annual Meeting opens May 13 at the Hilton Chicago for four days of research presentations spanning melanoma biology, hair follicle science, microbiome-immune interactions, and inflammatory skin disease. The late-breaking abstract drawing the most attention is a Corvus Pharmaceuticals filing titled Soquelitinib, an ITK inhibitor, Produces Prolonged Drug-Free Remissions in Atopic Dermatitis, scheduled for Saturday morning. If the data hold up in larger trials, the headline finding would mark a structural break from the chronic-suppression model that defines current eczema care. ## A Different Place in the Immune Cascade Soquelitinib is an oral, selective small-molecule inhibitor of interleukin-2-inducible T-cell kinase, an enzyme expressed predominantly in T cells. Most current systemic eczema therapies act further downstream. Dupilumab and lebrikizumab block IL-4 and IL-13 cytokine signaling at the receptor. JAK inhibitors like upadacitinib and abrocitinib block intracellular kinases shared across many cytokine pathways. ITK sits upstream of those signals, inside the T cell, at the point where T-cell receptor activation tells the cell which kind of inflammatory program to run. Selective ITK inhibition, in preclinical work published in Science Signaling and in murine models of T-cell-mediated inflammatory disease, shifts T-cell differentiation away from Th2 and Th17 programs (the drivers of atopic dermatitis lesions) and toward Th1 and regulatory T-cell activity. The clinical signal in the Phase 1 trial included reductions in serum IL-4, IL-5, IL-17, and thymus and activation-regulated chemokine, alongside a decrease in circulating Th2 cells. ## How Does Drug-Free Remission Differ From Current Eczema Treatment? Drug-free remission means a patient stops taking the drug and the disease does not return for an extended interval. Every approved systemic therapy for moderate-to-severe atopic dermatitis is designed for indefinite use. Dupilumab is an every-two-week injection. JAK inhibitors are daily tablets. Stopping any of them generally returns the disease within weeks. The soquelitinib late-breaker is reporting sustained clinical improvement after treatment was discontinued, supported by new immunologic and biomarker data Corvus is presenting at the meeting. That distinction matters because chronic medication use accumulates exposure, cost, and risk. A therapy that resets immune programming and then steps away changes the economics, the safety conversation, and the long-term identity of patients living with the disease. ## What the Phase 1 Trial Tested The randomized, blinded, placebo-controlled Phase 1 study enrolled adults with moderate-to-severe atopic dermatitis across four ascending-dose cohorts. Cohort 4 results, reported in the first quarter of 2026, confirmed the earlier signal: sustained clinical improvement with extended treatment, with the biomarker pattern (lower Th2 cytokines, reduced circulating Th2 cells) consistent across patients. The SID presentations represent the final integrated readout. Two oral sessions are scheduled: Immunologic and clinical activity of soquelitinib in patients with moderate-to-severe atopic dermatitis on Thursday, May 14, and the late-breaking drug-free remission abstract on Saturday, May 16 at 10:40 am Central. Corvus is hosting a parallel investor and analyst meeting Thursday afternoon, May 14, 1:30 to 2:30 pm Eastern, to brief on the data. ## What Comes After the SID Readout? A Phase 2 trial began in the first quarter of 2026, enrolling approximately 200 patients with moderate-to-severe atopic dermatitis who failed at least one prior topical or systemic therapy. The 12-week protocol tests multiple dosing regimens. The Phase 2 design will determine whether the drug-free remission signal scales beyond the small Phase 1 cohort, whether the biomarker pattern predicts which patients sustain remission, and how soquelitinib compares against the current standard of care in a powered head-to-head context. The broader SID 2026 program reaches well past one drug. Thursday's featured lectures span melanoma therapeutics, hair follicle biology, clinical epidemiology, and microbiome-immune interactions. The microbiome-immune lecture in particular will be watched by formulators and ingredient developers who follow how the cutaneous microbial community talks to skin immune cells, the conversation that explains why barrier disruption and dysbiosis tend to travel together in atopic dermatitis and rosacea. Friday and Saturday continue with psoriasis genomics and named lectures across the field. For readers who track skincare science, the soquelitinib data are the headline because they propose a different conceptual model of what a disease-modifying therapy in dermatology looks like. The rest of SID 2026 fills in the basic biology that informs what comes after the headline.